Retatrutide: Tracking a Triple-Agonist Weight-Loss Compound

Retatrutide is an investigational triple agonist developed by Eli Lilly, active at the GLP-1, GIP, and glucagon receptors. Its Phase 3 program (TRIUMPH) has now reported: TRIUMPH-1 in May 2026 showed roughly 28 percent average body-weight reduction at 80 weeks in adults with obesity, among the largest magnitudes reported in this drug class, with the earlier TRIUMPH-4 readout in the same range. Despite those results it is still not FDA-approved as of mid-2026 - the regulatory filing is expected around late 2026, with approval unlikely before 2027-2028. This post is about how to think about tracking on a triple-agonist, with the explicit caveat that any non-trial use is off-label and should involve a physician - full stop.

What it does

Retatrutide acts on three receptors at once. Each contributes something distinct:

• GLP-1 agonism — appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion. The mechanism behind semaglutide and liraglutide.
• GIP agonism — insulin secretion and lipid handling. Adds the "tirzepatide" dimension.
• Glucagon agonism — increases energy expenditure and supports lipolysis. This is the new lever versus tirzepatide and is also the trickiest one to balance.

The glucagon component is what makes this class different from GLP-1-only or GLP-1/GIP agents — and it is also why titration and tracking matter more, not less.

Typical protocol shape

• Subcutaneous injection, typically once weekly given the long half-life
• Slow titration — starting low and increasing every 4 weeks, like other agents in this class
• Cycle is open-ended in trials, with maintenance phases

Specific doses in trials vary by phase and are not recommendations. Off-trial use should be physician-supervised.

What to track daily

Multi-agonist therapy produces overlapping effects that need to be teased apart:

• Appetite score (1-10) at meals
• Nausea and GI symptoms — severity and timing relative to dose day
• Hydration and water intake
• Energy level
• Sleep quality
• Resting heart rate
• Food intake — actual, not estimated. Photos work.

What to track weekly

• Body weight at a fixed time, fixed conditions
• Waist circumference
• Blood pressure
• Average resting heart rate
• Side-effect summary — what cleared, what persisted

Peptid AI's titration view groups daily metrics by dose-level segment, which is the right way to see whether a side effect belongs to the compound or to a specific dose tier.

Bloodwork worth doing

This is a class where labs are non-optional, especially given the glucagon component:

• Fasting glucose and HbA1c
• Lipid panel
• Liver enzymes — glucagon agonism can affect hepatic glucose handling
• Kidney function — dehydration risk from GI side effects
• Thyroid as baseline
• CBC and CMP

Repeat at each dose escalation if practical, and at minimum every 12 weeks.

Realistic expectations

Phase 2 data showed substantial weight loss at higher doses over many months, but those results came alongside structured medical supervision, gradual titration, and high rates of GI side effects, particularly during dose increases. A reasonable framing: expect appetite reduction within weeks, expect weight loss to develop over months, expect side effects to be most intense during titration, and expect to have to adjust slower than you want to.

Common mistakes

1. Titrating too fast. The class punishes this with nausea, vomiting, and dehydration.
2. Not eating enough protein. Rapid weight loss without adequate protein costs lean mass.
3. Skipping resistance training. Same reason.
4. Treating it as a one-tool solution. Diet, training, sleep, and stress all still matter and are easier to dial in when appetite is suppressed.
5. No baseline labs. This compound moves multiple metabolic systems. You need a before.

A tracking template

Weeks -2 to 0: baseline labs, daily metrics, no dose. Weeks 1-16: titration phase. Daily metrics, weekly weight, labs at each escalation. Weeks 17 onward: maintenance dose. Continue daily and weekly metrics. Labs at week 24.

If you stop, log the discontinuation carefully — weight regain patterns in this class are well-documented and worth tracking honestly.

Safety notes

Retatrutide is investigational. Any use outside a trial setting is off-label and carries real risk: pancreatitis, gallbladder events, severe GI effects, dehydration, and unknown long-term effects from the glucagon component. Do not run this without a physician. Track everything, and stop and call your clinician if anything escalates.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.